导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -7.92% | 3593/4745 |
| 近一周 | -1.70% | 3119/5428 |
| 近一月 | -3.52% | 1261/5382 |
| 近一季 | 0.95% | 859/5200 |
| 近半年 | -6.56% | 3356/4900 |
| 近一年 | -12.88% | 3507/4374 |
| 近两年 | 38.25% | 1950/2939 |
| 近三年 | 34.99% | 890/2239 |
| 成立以来 | 50.82% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-5.57% 3875/4961 |
-9.34% 3957/5312 |
- - |
- - |
| 2025 | 28.27% 1495/4813 |
15.83% 155/3635 |
3.83% 937/4076 |
12.72% 3042/4524 |
-5.38% 3548/4813 |
| 2024 | 25.65% 252/3463 |
-1.41% 183/280 |
10.97% 18/310 |
17.90% 1101/3129 |
-2.59% 2141/3463 |
| 2023 | -12.86% 1513/2656 |
0.29% 155/205 |
-0.64% 124/230 |
-8.36% 217/262 |
-4.58% 222/276 |
| 2022 | -4.85% 111/2207 |
-7.98% 51/153 |
6.46% 49/164 |
-14.76% 97/189 |
13.95% 60/202 |
| 2021 | -12.14% 1124/1822 |
5.16% 66/312 |
0.71% 212/328 |
-12.01% 235/358 |
-5.71% 80/151 |
| 2020 | -6.27% 973/1250 |
-14.10% 183/280 |
4.35% 231/295 |
-7.02% 282/299 |
12.46% 88/305 |
| 2019 | 13.35% 707/1092 |
9.84% 126/258 |
1.71% 123/268 |
-5.49% 227/253 |
7.36% 110/266 |
| 2018 | -8.00% 67/834 |
- - |
- - |
- - |
-7.17% 85/241 |
| 2017 | 28.81% 12/69 |
- - |
- - |
- - |
- - |
| 2016 | 8.48% 20/59 |
- - |
- - |
- - |
- - |
| 2015 | -3.25% 24/49 |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 广发中证香港创新药ETF(QDII) | 1.2946 | 31.47% |
| 广发中证香港创新药ETF发起式联接(QDII)C | 1.3488 | 29.79% |
| 汇添富恒生生物科技ETF(QDII) | 1.1245 | 29.24% |
| 南方恒生生物科技ETF(QDII) | 1.1400 | 29.08% |
| 广发道琼斯石油指数美元现汇A | 0.4638 | 27.44% |
| 广发道琼斯石油指数美元现汇C | 0.4557 | 27.38% |
| 广发道琼斯石油指数(QDII-LOF)美元现汇E | 0.4568 | 27.33% |
| 南方恒生生物科技ETF发起联接(QDII)A | 1.2646 | 27.30% |
| 华夏恒生生物科技ETF发起式联接(QDII)C | 1.1472 | 27.25% |
| 汇添富恒生生物科技ETF发起式联接(QDII)C | 1.6358 | 27.22% |
| 南方恒指ETF VS. 建信富时100指数(QDII)人民币A(539003) |